NeuVasQ was founded based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB). The BBB regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well asmultiple acute neurological conditions like stroke and epilepsy.
The company will develop first-in-class pharmaceuticals exploring different therapeutic modalities based on gene, RNA, small molecules or antibody/protein construct. Proof-of-Concept data of Animal models for stroke and glioblastoma have been published in the academic journal “Science”.


Acticor Biotech

Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. It has developed a product from a fragment of an antibody (Glenzocimab) targeting the platelet Glycoprotein VI to accelerate the thrombus dissolution rate in acute ischemic stroke treated with thrombolysis, without increasing the risk of bleeding. The product is developed as an add-on therapy to thrombolysis treatment in thrombo-embolic diseases. The two major ongoing clinical trials are the ACTIMIS project (a Phase IIa study, placebo controlled, to document safety in ischemic stroke and the ACTISAVE project (an international US – EU Phase II-III adaptive randomized placebo-controlled trial in ischemic stroke).



Synergia Medical is pioneering optoelectronics for medical devices for neurostimulation, replacing the metallic wires of a traditional neurostimulator by optical fibers and using photovoltaic cells to convert light into electrical impulses. The device incorporates innovations in biomaterials, micro-electronics, optical components and biosensors. The first application is a neurostimulation device, which stimulates the vagus nerve, for the treatment of refractory epilepsy. Vagus nerve stimulation has been shown to reduce epileptic seizures by sending regular, mild pulses of electrical energy to the brain via the vagus nerve.